OptoCeutics is Presenting at The 15th Clinical Trial on Alzheimer’s Disease (CTAD 2022)

Copenhagen, Denmark, 24 November 2022 – OptoCeutics ApS (”OptoCeutics” or ”The Company”) is pleased to inform that they will be presenting at the 15 TH Clinical Trial on Alzheimer’s Disease NOVEMBER 29- DECEMBER 2, 2022 (“CTAD 2022”).

OptoCeutics has successfully collaborated with its partners at Zealand University Hospital and the Technical University of Denmark since its conception in 2018 to complete their first clinical trials on the safety and feasibility of their 40 Hz gamma light stimulation device for Alzheimer’s disease (AD).

With results from the recently completed trial, “Study on Safety, Feasibility, and Neural Activation of Non-Invasive Light Therapy System” (“ALZLIGHT Pilot”, ClinicalTrials.gov Identifier: NCT04574921), OptoCeutics will be presenting at CTAD 2022.

The company will share data on the safety and feasibility of their gamma light stimulation device from the ALZLIGHT Pilot clinical trial.

Marcus Carstensen, technical director at OptoCeutics, says: “We are excited to finally share the safety and feasibility results for ALZLIGHT Pilot. Zealand University Hospital, the Technical University of Denmark, and OptoCeutics have spent a lot of time since 2018 on the ALZLIGHT clinical trial, while simultaneously certifying the light-based brain stimulation system as a Class I medical device under MDR”.

For further information, please contact: Marcus Schulz Carstensen, CTO
OptoCeutics ApS
+45 23 45 64 42
msc@optoceutics.com